BioMarin Five-Year Pompe Therapy Data Released
The results demonstrate sustained respiratory function and mobility in patients with late-onset Pompe disease.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you believe long-term clinical data is sufficient to prove medical therapies benefit patients?
BioMarin has released five-year clinical trial data for Pombiliti and Opfolda, a combination therapy designed to treat late-onset Pompe disease. The study tracked 82 participants, showing that the treatment maintained walking distance and respiratory function over the duration of the trial.
Why it matters
Late-onset Pompe disease causes progressive muscle weakness that leads to significant physical impairment over time. This long-term data provides evidence on the stability of these key functional markers during the course of the therapy.
The study followed 82 patients across both those new to enzyme replacement therapy and individuals who had received previous treatment. Results showed that respiratory function remained stable and no new safety signals emerged over the five-year period.
The players
BioMarin
A biotechnology firm that develops therapies for rare genetic diseases and expanded its portfolio through the acquisition of Amicus Therapeutics.
World Muscle Society
An international medical organization focused on neuromuscular disorders that hosts an annual congress to review clinical research.
The details
Pompe disease is a genetic condition that results in the accumulation of glycogen in cells, leading to progressive muscle weakness. Pombiliti and Opfolda function as a combination therapy to manage the symptoms of this condition by replacing the deficient enzyme. The study presented at the World Muscle Society tracked these functional outcomes to determine if the therapeutic approach could mitigate the decline in physical mobility.
Timeline
December: BioMarin acquired Amicus Therapeutics.
October 2, 2026: BioMarin released five-year clinical trial data at the 31st annual Congress of the World Muscle Society.
The Tech Race
The industry standard for demonstrating the durability of rare disease treatments remains long-term clinical trial data presented at major medical forums. By reporting these five-year results, BioMarin aligns its therapeutic outcomes with the benchmarks required for establishing sustainable treatment for chronic neuromuscular conditions.
Patients and clinicians can use these long-term results to better understand the expected stability of respiratory and physical function when using this therapy. The data confirms the five-year safety profile of the treatment for both new and previously treated patients.
The takeaway
The sustained functional stability observed over five years suggests that this therapy remains a viable clinical option for managing the progression of late-onset Pompe disease. Stakeholders should watch for future updates regarding the integration of Amicus Therapeutics assets following the December acquisition.
Further reading
For more on the current landscape of rare disease research, visit Biotech.
Live Poll
Do you believe long-term clinical data is sufficient to prove medical therapies benefit patients?
